Impaired clearance of amyloid-b peptide (Ab) leads to abnormal extracellular accumulation of this neurotoxic protein that drives neurodegeneration in sporadic Alzheimer's disease (AD). Connective tissue growth factor (CTGF/CCN2) expression is elevated in plaque-surrounding astrocytes in AD patients. However, the role of CTGF in AD pathogenesis remains unclear.
Introduction
The accumulation of amyloid-b peptide (Ab) in the brain leads to progressive neuronal loss in Alzheimer's disease (AD), the most common form of dementia (1) . Strong correlation is observed between the severity of cognitive impairment in AD and the levels of oligomeric rather than aggregated Ab in senile plaques (2, 3) . In a healthy brain, Ab homeostasis is maintained by a balance between its production and clearance, whereas in AD brain overproduction and/or reduced clearance of Ab result in the formation of amyloid deposits (4) . Recent evidence suggested that the impairment of Ab clearance was the major cause of sporadic late-onset AD (5) , suggesting that therapeutic approaches targeting Ab clearance may be beneficial for the treatment of AD (6) . We and others have shown that both neurons and glia can clear extracellular Ab through endocytosis for subsequent lysosomal degradation or secretion of amyloiddegrading enzymes for extracellular clearance (4, 7) . Glial cells respond to nearly all types of central nervous system (CNS) insults or neurodegenerative diseases, including AD. These glial responses, so called "reactive gliosis", range from upregulation of gene transcription to enhanced secretion of matricellular proteins for remodeling of extracellular matrix (ECM) surrounding the neurons (8, 9) . Many signaling molecules secreted by reactive glia have been proposed to mediate neuron-glia interactions in AD pathogenesis (10) . Reactive gliosis is often found in close proximity to amyloid plaques, and is in positive correlation with the progression of AD. However, it remains controversial whether these responses are beneficial or detrimental to neuronal survival (11) .
The CCN (CYR61/CTGF/NOV) family proteins play a role in multiple processes including proliferation, apoptosis, and cell migration in non-CNS tissues and the nervous system (12) . Connective tissue growth factor (CTGF/CCN2) is a secreted protein of the CCN matricellular protein family, which expression is upregulated and affects connective tissues under pathological conditions such as fibrosis and cancer. Therefore, it has been proposed as a tumor suppressor or potential therapeutic target for lung and ovarian cancers and fibrosis (13) (14) (15) . Notably, CTGF is also found in glial cells and cortical neurons of both rat and human brains (16) (17) (18) . It is further upregulated in glia upon acute brain injury such as stroke (19) , spinal cord injury (20) , or neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) (21) and AD (22) . In a mouse AD model, CTGF expression in the brain is increased upon diabetic challenge (23) . In the brains of AD patients, the upregulation of CTGF was striking around amyloid plaques (22) . However, whether CTGF exerts a protective role and mediates neuron-glia communication in AD pathogenesis remains unknown.
Matrix metalloproteinases (MMPs) are a large family of zinccontaining endoproteases whose role has been demonstrated in degrading ECM proteins and tissue remodeling (24) . Enhanced expression of MMP-2 and MMP-9 has been found in astrocytes surrounding amyloid plaques and in the neurons and glia of the hippocampus after intracerebroventricular Ab injection (25) (26) (27) (28) . Increasing in vitro evidence indicates that some MMPs may play an important role in degrading soluble Ab (sAb), such as secreted MMP-2 and MMP-9 that generate C-terminally truncated Ab fragments and membrane-type MMP-14 that degrades both soluble and fibrillary Ab (29) (30) (31) (32) . CTGF has been shown to induce the expression of specific MMPs in several pathophysiological conditions, including MMP-2 in both retinal neovascularization (33) and diabetic nephropathy (34) , MMP-2 and MMP-3 in tumor metastasis (35) , and MMP-3 and MMP-13 in osteoarthritis (36) . However, the identity of MMPs activated by CTGF for degradation of Ab in AD pathogenesis remains unknown.
Despite countless efforts to design therapeutic strategies for AD, no effective therapy is currently available. Here, we investigated the neuroprotective effects of CTGF in both neuronal and glial cultures in addition to Ab42-expressing fly model of AD. The fruit fly Drosophila has been used as a genetic model to study AD pathogenesis in vivo by expressing the transgene of amyloidogenic human Ab42 coupled to a secreted peptide in the nervous system. The fly model of AD displays many features of the disease, including Ab deposition in the brain, neuronal degeneration, locomotor dysfunction, and memory deficits (37-39).
Furthermore, the tissue-specific expression system of Drosophila allows us to examine the in vivo interactions between neurons and glia in the CNS. Our findings in mammalian cells show that upon Ab challenge, CTGF is induced specifically in glia, and not in neurons. CTGF promotes both the intake of Ab for lysosomal degradation and degradation of extracellular Ab via the MMPs. To reveal the glial function of CTGF, we perform targeted CTGF expression in glia, and reveal the neuroprotection by CTGF in ameliorating both morphological defects and functional impairment caused by Ab accumulation. Neuroprotective effects are disrupted by silencing the MMPs. Thus, CTGF promotes Ab degradation via MMPs to reduce Ab accumulation in AD pathogenesis. Our findings describe a novel form of glia-neuron communication via CTGF to alleviate Ab neurotoxicity.
Results
CTGF enhances the uptake and extracellular degradation of soluble Ab by glial cells CTGF immunolabeling has been detected in the brains of human AD patients (22) . Therefore, we aimed to explore the role of CTGF in neurons and in reactive gliosis upon Ab challenge. We first showed that the levels of CTGF were higher in the cortex of Fig. S1G ). These results suggested the tissue-specific induction of CTGF upon AD pathogenesis. To investigate its effect on glial response to Ab challenge, we incubated mixed glial cells with rCTGF in the presence of sAb. Using Western blot we observed a gradual reduction in remaining sAb within the media at indicated time points (Fig. 1A) , which was dependent on rCTGF concentration (Fig. 1B) . A control experiment showed that adding sAb to CTGF-containing cell-free media did not change the Ab profile (Supplementary Material, Fig.  S2 ). Thus, rCTGF promoted glial uptake and/or extracellular degradation of sAb. To visualize the Ab uptake, we incubated rCTGF-pretreated mixed glial cells with Ab and examined subcellular immunofluorescence of Ab using confocal microscopy. An increase of punctate intracellular Ab was observed in both rCTGF-treated astrocytes (Fig. 1C) and microglia ( Fig. 1D) compared to vehicle-treated control. The internalization of Ab was verified by ELISA after subjecting the cells to trypsinization to digest the surface-bound Ab. An increase in Ab levels was detected, indicating that CTGF facilitated glial uptake of Ab (Fig.  1E) . We previously showed that internalized sAb was trafficked into lysosomes for degradation in microglia (7) . Thus, we tested whether CTGF would facilitate the subsequent degradation by performing a pulse-chase experiment. Mixed glial cells were pre-treated with rCTGF, followed by 4 h incubation with sAb.
After washout, intracellular Ab levels were examined at the indicated chase periods. Intracellular Ab level was significantly lower at 1 h after sAb incubation, but no difference was observed at other time points compared to vehicle-treated control (Fig. 1F) . Taken together, CTGF promotes both the uptake and subsequent degradation of Ab in glial cells.
CTGF-mediated extracellular degradation of soluble Ab is dependent on matrix metalloproteinase 14 in glia
We then asked whether CTGF could stimulate the glia to degrade extracellular sAb. MMPs have been shown to degrade extracellular sAb, similar to several other proteases, including endothelin-converting enzyme (ECE), insulin-degrading enzyme (IDE), neprilysin (NEP) (31, 40, 41) . To identify potential CTGFinduced sAb-degrading proteases, we profiled the mRNA abundance of these proteases in rCTGF-treated mixed glial cells by quantitative PCR (qPCR). Upon rCTGF incubation, the mRNA of both MMP-13 and -14 was significantly upregulated, compared to non-treated control ( Fig. 2A , and Supplementary Material, Fig. S3A ). We then checked protein levels by Western blot, and found an increase only in MMP-14 upon rCTGF treatment ( Fig.  2B and C) . To examine whether rCTGF functions through MMP-14 to degrade sAb, the pan-MMP inhibitor batimastat (42) was added to rCTGF-pretreated mixed glial cells. We observed a complete abolishment of sAb clearance (Fig. 2D) . MMP-14 is membrane-bound, and incubation of MMP-14-specific antibody can reduce its protease activity in endothelial cells (43) . Thus, we incubated glial cells with the antibody to block the enzymatic activity of MMP-14, and observed a reduction in sAb degradation by rCTGF compared to IgG antibody control (Fig. 2E) . Thus, CTGF stimulates glial cells to produce MMP-14 for extracellular clearance of sAb.
CTGF enhances cellular uptake and degradation of soluble Ab by neuronal cells
We then asked whether rCTGF would affect the clearance of Ab in SH-SY5Y cells. rCTGF lowered the level of remaining Ab within the media in a time-and dose-dependent manner, similar to our observation in mixed glial cells (Fig. 3A and B) . Likewise, the intracellular uptake of Ab was increased in rCTGF-treated SH-SY5Y cells ( Fig. 3C and D) . Notably, we observed an increased colocalization of intracellular Ab with lysosomal-associated membrane protein (LAMP) 1 upon rCTGF treatment (Fig. 3C ). In addition, the pulse-chase experiment showed enhanced efficiency of intracellular Ab degradation at a later time point (Fig. 3E) . The lysosomal inhibitor chloroquine significantly reduced intracellular Ab degradation (Fig. 3F) , further supporting lysosomal degradation of Ab. Thus, similar to its effect on glial cells, rCTGF enhances not only sAb uptake but also subsequent degradation in neuronal cells. Although neuronal cells failed to produce CTGF in response to Ab, they responded to rCTGF by clearing intracellular Ab. 
CTGF-mediated extracellular degradation of soluble Ab is dependent on neuronal matrix metalloproteinase 13
We then examined whether CTGF also enhanced extracellular Ab degradation by neurons. We quantified the mRNA for MMPs in rCTGF-treated SH-SY5Y cells by qPCR, and observed a significant upregulation of MMP-13 compared to non-treated control (Fig. 4A , and Supplementary Material, Fig. S3B ). The increase in MMP-13 at the protein level was verified by Western blot ( Fig. 4B and C). MMP-13 is a secretory protease, so we asked whether rCTGF was functioning through MMP-13 to degrade extracellular sAb. The neuronal conditioned medium (NCM) was prepared as depicted in Figure 4D and in the Materials and Methods. sAb was added to NCM of rCTGF-treated neurons (rCTGF-NCM) for 24 h, and Ab was quantified by Western blot (Fig. 4D) . A reduction in the abundance of Ab in the NCM was apparent (Fig. 4E) . Thus, CTGF also promotes sAb clearance by neurons by enhancing extracellular degradation. Interestingly, drug inhibition of MMP-13 by batimastat added to the rCTGF-NCM completely abolished the sAb clearance (Fig. 4F) . To investigate the capacity of neuronal MMP-13 to degrade sAb, we established two stable SH-SY5Y clones of independent shRNA targeting MMP-13 (Supplementary Material, Fig. S4 ). These clones blocked rCTGFinduced degradation of sAb by NCM, resulting in the accumulation of sAb (Fig. 4G) . As a control, the two shMMP-13 clones were added to vehicle-treated NCM, which did not result in sAb accumulation. Then, we examined whether recombinant MMP-13 (rMMP-13) can directly degrade sAb in vitro. sAb was gradually degraded after incubation with rMMP-13 for 24 h, indicating that sAb is a direct substrate for MMP-13 ( Fig. S5B ). Ab accumulation was examined by confocal microscopy analyses of immunoreactivity for anti-Ab antibody 4G8. In the brains of 21-day-old transgenic Ab42 flies, we observed the presence of abundant 4G8-positive puncta, the number and intensity of which were both reduced by neuronal expression of CTGF (Fig. 5A) . Thioflavin-S (Thio-S) stains for Ab deposits-containing amyloid fibril structures (46) . Using Thio-S staining in the Ab42 brain, we observed more extensive vacuolization surrounded by aggregated Ab, which was reduced when CTGF was co-expressed ( Fig.  5B and E) . We verified the immunohistochemical findings using ELISA analysis, and observed that CTGF co-expression significantly reduced SDS-soluble Ab42 and SDS-insoluble/formic acid-soluble Ab42 compared to the Ab control brain (Fig. 5C and  D) . Thus, CTGF is capable of clearing Ab accumulation and reducing the neuronal loss in the fly brain. We then asked whether CTGF expression could improve neuronal function in individuals affected by Ab. Flies with neuronal expression of Ab42 demonstrated a progressive decrease in climbing ability at day 7 that was exacerbated at day 21, as shown in Figure 5F and by Iijima et al (38) . Co-expression of CTGF in Ab flies restored locomotor dysfunction to the levels comparable to those in the controls, whereas expression of CTGF alone had no effect on locomotor activity (Fig. 5F ). This effect was gender-independent, as both male and female Ab42 flies displayed locomotor dysfunction that was rescued by CTGF co-expression (Supplementary Material, Fig. S6 ). Furthermore, we examined whether CTGF could reverse the memory loss in AD fly. We performed Pavlovian olfactory associative learning paradigm to assess the memory function. No significant defect was observed in 7-day-old wild type or CTGF-expressing flies that were used as controls. In contrast, in 7-day-old flies, neuronal expression of Ab resulted in a significant decline in olfactory learning performance, which was exacerbated in 21-day-old AD flies and rescued to control levels by neuronal co-expression of CTGF (Fig. 5G) . Thus, neuronal expression of CTGF can ameliorate functional consequences of Ab-induced neurodegeneration by reducing Ab accumulation in the brain.
Silencing MMP expression impaired CTGF-induced neuroprotection in the eyes of AD fly
Next, we asked whether, similar to what we observed in cultured cells, MMPs were required for CTGF to exert its neuroprotective function in flies. Compound eyes of flies are comprised of ommatidia with organized bundles of photoreceptors, each of which contains a rhabdomere, a specialized phototransductive structure known to degenerate upon neurotoxic challenge with amyloidogenic Ab42 (47) . Ectopic expression of Ab42 using eye-specific driver GMR-Gal4 led to a progressive disorganization of photoreceptor margins and a reduction in the number of rhabdomeres ( Fig. 6A and B) . Co-expression of CTGF significantly rescued Ab42-induced morphological defects in photoreceptors ( Fig. 6A and B) . The overexpression of CTGF alone as a control had no effect on the ommatidia (data not shown). In the fly genome, there are only two known mmp genes, which encode the secreted dMMP-1 and the membrane-bound dMMP-2, respectively (48,49). The expression of dMMP-1 or dMMP-2 can be silenced by its corresponding RNAi (50) . We showed that knockdown of either dMMP in the eye did not change the photoreceptor morphology, indicating that eye development was not affected (Supplementary Material, Fig. S7 and S8) . However, knockdown of dMMP-1 or dMMP-2 disrupted the protective effect of CTGF when Ab42 and CTGF were co-expressed, as we observed the reduction in the numbers of rhabdomeres as compared to Ab42 flies ( Fig. 6C and D) . Thus, CTGF attenuated the degeneration of photoreceptors through the MMPs in the fly model of AD.
Glia-secreted CTGF prevents Ab-induced toxicity in AD fly
Finally, we addressed the role of CTGF in reactive gliosis in the fly model. To achieve glia-specific expression of CTGF, we generated a transgenic repo-CTGF allele by fusing CTGF cDNA to the promotor of the reversed polarity (repo) system. We then investigated whether glial CTGF would reduce Ab42-induced neurodegeneration in flies. The expression of CTGF in glial cells significantly decreased rhabdomere numbers compared to Ab42 flies ( Fig. 7A and D) . Also, the glia-specific expression of CTGF reduced the numbers of 4G8-positive puncta and Thio-S labeled Ab aggregates in aged Ab flies (Fig. 7B and C) . The level of vacuolization was significantly decreased by glial-specific expression of CTGF (Fig. 7E) . The Ab-induced defect in olfactory associative learning was also rescued by glial expression of CTGF (Fig. 7F) , similar to our findings following CTGF expression in neurons (Fig. 5G) . In summary, these results suggest that CTGF expressed by glia can exert cell non-autonomous neuronal protection from Ab-induced toxicity (Fig. 7G) .
Discussion
In sporadic late-onset AD, decreased clearance has recently been evoked as the dominant mechanism leading to elevated Ab levels (5) . In this work, we show for the first time that CTGF exerts its protective effects by promoting Ab clearance, thus attenuating Ab-induced neurotoxicity in both cellular and animal models. By examining both neuronal and glial cultures, we observed that mixed glial cells, but not neuroblastoma cells, responded to sAb stimulation by elevating the levels of CTGF. CTGF enhanced not only sAb uptake and lysosomal degradation but also extracellular sAb degradation through the MMPs. We further tested the effects of CTGF in vivo, and found that both neuronal-and glial-specific expression of CTGF significantly reduced Ab synaptotoxicity and ameliorated memory deficits in a fly model of AD. Neuroprotective effects of CTGF against Ab neurotoxicity required the MMPs in the fly model. Therefore, we propose a mechanism wherein, upon Ab challenge, glia produces CTGF to enhance the clearance of Ab through the MMPs, hence preventing the neurotoxicity and improving memory function (Fig. 7F) . These findings provide a functional link in neuron-glia communication through CTGF-MMP pathway against Ab-induced CNS degeneration. To our knowledge, this is the first study to demonstrate the neuroprotective effect of CTGF in the pathogenesis of AD in vivo.
In a normal human brain, CTGF immunoreactivity was detected in layers III and V pyramidal neurons (22) . Although CTGF expression was up-regulated in tissues surrounding the amyloid plaques in the brains of AD patients (22, 23) , little is known about the underlying causes leading to CTGF induction. We have observed that sAb induced the up-regulation of CTGF specifically in cultured glial cells. Although neuronal expression of CTGF is not induced, rCTGF supplementation to the culture medium of neuronal cells increased the protein levels of CTGF without affecting its mRNA abundance (data not shown). It is possible that neurons initially uptake CTGF secreted by adjacent glial cells during the progression of AD. In support of this possibility, CTGF can be internalized into the cytosol by human mesangial cells and exert its protective effect against diabetic nephropathy (51) . This perspective underscores the neuroprotection by glia through CTGF in AD. However, it still awaits investigation whether stimulation of CTGF activity may exert neuroprotection in APP/PS1 transgenic mouse AD model, or if high CTGF levels were associated with better prognosis in human AD patients. In addition to AD, in spinal cord injury model of zebrafish, CTGF was up-regulated in and/or around glial cells of the lesion areas. Transgenic expression of zebrafish CTGF or treatment of human recombinant CTGF both increased axonal growth and glial bridge formation in the repair process of (20) . Moreover, levels of CTGF also increase in traumatic brain injury and amyotrophic lateral sclerosis (18, 21) . Thus, whether CTGF also protects against other forms of neurotoxic insult needs further elucidation.
Several forms of reactive gliosis have been proposed to exert neuroprotection in AD. For example, TGF-b was secreted by reactive glial cells upon Ab challenge, and TGF-b enhanced Ab clearance by microglia resulting in neuronal protection from Ab toxicity (52, 53) . In our study, CTGF was increased in glial cultures after sAb stimulation. Glia-specific secretion of CTGF ameliorated both morphological and functional defects caused by neuronal expression of Ab in a fly model of AD. These results suggest a novel form of neuron-glia communication whereby glia-derived CTGF protects neurons from Ab toxicity. This CTGF pathway may provide a potential therapeutic target for treating AD. Furthermore, CTGF increased levels of MMP-13 and MMP-14 proteins in neurons and glial cells, respectively. Thus, MMPs may be activated by CTGF in a cell-type specific manner. In addition, we have shown that the two MMPs exhibited CTGFdependent Ab-degrading activity, with MMP-13 acting in neurons and MMP-14 in glia. To our knowledge, this is the first report describing MMP-13 as an Ab-degrading enzyme. Further investigation is needed to elucidate the mechanisms by which CTGF differentially activates MMP-13 in neurons and MMP-14 in glia.
The fly model of AD has been used for targeted panneuronal expression of secreted human amyloidogenic Ab42 peptide in Drosophila (38) . No obvious homolog of CTGF has been identified in the fly genome, making it a clean system to examine the neuroprotection of ectopic CTGF expression. We show that human CTGF significantly improves the agedependent, AD-like neuropathology and behavioral deficits in the fly model of AD. It is possible that CTGF employs evolutionarily conserved machinery for Ab clearance. In support of this, we show that CTGF functions through the MMPs in both mammalian cultures and fly system. There are only two MMPs in Drosophila, the secreted dMMP-1 and membrane-anchored dMMP-2 (32, 48) . These MMPs function in several processes including neural development, tissue remodeling, and tumor progression (24, 49, 54, 55) . Our findings indicate that the protective effect of CTGF in photoreceptors is disrupted by silencing either of the dMMPs, suggesting that these may be the effectors for CTGF activity. However, overexpression of dMMP-1 did not rescue Ab-induced neurodegeneration in the eye of the fly model of AD, and overexpression of dMMP-2 even aggravated the eye morphology (data not shown). It is possible that gain of MMP activities causes neurodegeneration unrelated to CTGF function.
In conclusion, we show that CTGF exerts its neuroprotective effect against Ab neurotoxicity by activating the clearance machinery for misfolded/aggregated Ab. Impairment of Ab uptake and clearance by neurons, glia, and blood-brain-barrier endothelial cells may explain why the level of Ab is elevated and accumulates during AD progression (4). However, the endogenous CTGF is not sufficient to overcome the long course of continuous Ab burden, albeit enhanced expression of CTGF is found adjacent to amyloid plaques. We propose that selective activation of CTGF-MMP pathway in the CNS should be explored as a new therapeutic strategy for AD. As accumulation of misfolded/ aggregated proteins in the CNS is common to several neurodegenerative diseases including Parkinson's disease, Huntington's disease, and ALS, further studies are needed to examine whether activation of CTGF-degrading mechanisms may also protect neurons against the toxicity of other misfolded/aggregated proteins and subsequently decelerate the progression of these neurodegenerative diseases.
Materials and Methods

Reagents
Synthetic Ab1-42 and fluorescein amidite (FAM)-labeled Ab1-42 were purchased from American Peptide and Biopeptide, respectively. To prepare soluble Ab (sAb), Ab peptides were dissolved in dimethyl sulfoxide at 5 mM and then diluted into Ham's F-12 to a final concentration of 100 lM. The Ab solution was then incubated for 24 h at 4 C and centrifuged at 14,000 Â g for 10 min
to remove fibrillar and aggregated Ab. Recombinant human CTGF (rCTGF) was purchased from BioVendor. Antibodies against Ab (6E10 and 4G8) and anti-LAMP1 antibody were purchased from BioLegend. Anti-Caspase-3 antibody was purchased from Abcam. Anti-CTGF and anti-b-actin antibodies were purchased from Santa Cruz Biotechnology. Anti-GFAP and anti-Iba1 antibodies were purchased from WaKo. Anti-NeuN antibody was purchased from Millipore. Anti-Na
alpha-subunit antibody was obtained from Developmental Studies Hybridoma Bank (DSHB). Phalloidin-conjugated with Alexa Fluor-488 was purchased from Invitrogen. Alexa Fluor 488-, 594-, and 647-conjugated secondary antibodies were purchased from Jackson ImmunoResearch. Batimastat was purchased from Cayman.
Generation of transgenic flies and fly stocks
To generated UAS-CTGF flies, cDNA fragment of human CTGF was amplified by PCR and inserted into the pUAST vector by EcoRI and XhoI. For specific expression of CTGF in fly glia, human CTGF cDNA was cloned into pCaspeR4-Repo-SV40 vector by NotI and XbaI. The two plasmids were integrated into w1118 fly genome by P element-mediated integration (56) . UAS-Ab42 fly line was obtained from Bloomington Stock Center (BDSC). The UAS-dMMP1 RNAi and UAS-dMMP2 RNAi fly lines were obtained from the Drosophila RNAi Screening Center (DRSC). Flies were raised on standard cornmeal food at 25 C.
Cell cultures
Primary rat mixed glia were prepared as previously described (7). Briefly, meninges were removed from the cortices of neonates on postnatal day 1 and the cortices were dissociated by papain and endonuclease. Dissociated cells were grown in DMEM with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 lg/ml streptomycin at 37 C in a 5% CO 2 humidified atmosphere. The mixed glial cultures were incubated for 14 days prior to experiment. Primary rat microglia were separated from mixed glial cultures by gentle agitation after 14-day incubation.
Human neuroblastoma SH-SY5Y cells were maintained in 
, and Ab42 þ CTGF þ dMMP-2-RNAi, n ¼ 3) day-old flies of the indicated genotypes under GMR-GAL4. Statistically significant differences between the control and transgenic lines are indicated. *P < 0.05 using ANOVA. Scale bars in (A) and (C): 5 lm.
DMEM/F12 medium containing 10% FBS, 100 U/ml penicillin, and 100 lg/ml streptomycin.
Preparation of glial-conditioned medium (GCM)
Primary mixed glial cells (3 Â 10 5 ) were seeded in 12-well plates. These cells were treated with vehicle or sAb (10 lM) in serumfree medium for 48 h. The conditioned media were concentrated using the Amicon Ultra-0.5 concentration column (Millipore) according to the manufacturer's instructions. The total concentrated media (GCM) were analyzed by Western blot.
Soluble Ab uptake and degradation
Primary mixed glial cells (1 Â 10 5 ) and SH-SY5Y cells (5 Â 10 4 ) were seeded in 24-well plates overnight. These cells were pre-treated with rCTGF (0.1 or 0.5 lg/ml) in serum-free medium for 24 h, followed by incubation with sAb (1 lM). At the end of each time point, the conditioned media were collected and the remaining Ab in the media was analyzed by Western blot. To quantify Ab uptake, cells were harvested by incubating with trypsin for 5 min at 37 C, followed by three times of PBS wash. Cell pellets were lysed and Ab was analyzed using human Ab1-42 ELISA kit (Invitrogen) following the manufacturer's instruction. Results were normalized by total protein in each sample. For pulse-chase assay, rat mixed glial cells (2 Â 10 5 ) and SH-SY5Y cells (1 Â 10 5 ) were pre-treated with rCTGF, followed by incubation of soluble Ab (1 lM). For lysosomal degradation assay, SH-SY5Y cells were pretreated with chloroquine (10 lg/ml) for 1 h followed by the chase reaction. Cells were then washed with PBS and incubated with fresh media for the indicated times. Cell plates were harvested, lysed, and analyzed for Ab levels by ELISA.
Ab degradation in neuronal-conditioned medium (NCM)
SH-SY5Y cells (5 Â 10 4 ) were seeded in 24-well plates and then incubated with rCTGF (0.1 lg/ml) in serum-free medium for 24 h. Collected SH-SY5Y-conditioned medium (rCTGF-NCM) were incubated with soluble Ab (1 lM) for 24 h at 37 C. The Ab levels in the media were analyzed by Western blot. 
Transfection and stable transfected cell lines selection
The transfection was performed using Lipofectamine TM 2000
(Invitrogen) according to the manufacturer's instructions. Briefly, the pLKO or pLKO-shMMP-13 plasmids (National RNAi Core Facility, Academia Sinica, Taiwan) were mixed with Lipofectamine 2000 reagents for 20 min before adding into SH-SY5Y cells. After 24 h of transfection, the transfected cells were selected in puromycin (3 lg/ml) and the medium was replaced every 3 days for the generation of stable cell lines. After 2 weeks of selection in puromycin, clones of resistant cells were isolated and allowed to proliferate in the medium containing puromycin at 1 lg/ml. Integration of transfected plasmid DNA was confirmed by Western blot.
Western blot analysis
For Ab Western blot, samples were separated on a 16% polyacrylamide Tris-tricine gels and transferred to polyvinyidene difluoride (PVDF) membrane. Membranes were incubated with anti-6E10 antibody (1:1000) at 4 C for overnight, and then with anti-mouse IgG (1:5000) for 1 h at RT. For routine Western blot, samples were lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.4), 137 mM NaCl, 1% Triton X-100, 1 mM sodium deoxycholate, 1 mM EDTA, 1 mM EGTA, 1 mM NA 3 VO 4 , 50 mM NaF, and protease inhibitor cocktail. Protein samples were analyzed by 10% SDS-PAGE and transferred to PVDF membranes. After blocking, the membranes were incubated overnight at 4 C with primary antibodies for CTGF (1:1000), Caspase-3 (1:1000), MMP-13 (1:1000), MMP-14 (1:1000), and b-actin (1:5000). After incubation with secondary antibody, the immune complexes were detected with enhanced chemiluminescence reagents (Millipore) and images were obtained using a LAS-4000 imaging system (Fujifilm). The relative intensity of blot band was quantified by densitometry with Image J software.
Immunocytochemistry, immunohistochemistry, and confocal imaging
After the indicated treatment, cells were fixed with chilled methanol for 10 min, followed by incubation with primary antiAb antibody 6E10 (1:500), anti-GFAP antibody (1:1000), and anti-LAMP1 antibody (1:250) overnight at 4 C, individually. The cells were incubated with secondary antibodies conjugated to either Alexa Fluor-488 or -594 (1:500) for 1 h at RT. The coverslips were mounted in Vectashield (Vector Laboratories). Adult fly brains and eyes were dissected in PBS and fixed in 4% paraformaldehyde for 20 min at RT, followed by washed in 1% or 0.4% Triton X-100 in PBS (PBST). To analyze photoreceptor degeneration, fly eyes were staining with Alexa Fluor-488-conjugated phalloidin and anti-Na þ /K þ ATPase antibody (1:100) at 4 C overnight. After washing in PBST, tissues were incubated in goat anti-mouse IgG Alexa Fluor-647 antibody. To detect Ab expression in fly brains, tissues were staining with anti-Ab antibody 4G8 (1:250) at 4 C overnight, followed by incubation of goat anti-mouse IgG Alexa Fluor-488 antibody. To detect fibril Ab deposits, the fly brains were staining with 0.1% Thioflavin-S (Sigma) overnight at 4 C, followed by wash with 50% ethanol and PBS. The average number of vacuoles was measured by dividing the sum of the vacuoles within the indicated region (200 lm Â 120 lm) by the total flies of each group. Samples were analyzed on a Zeiss LSM780 confocal microscope (Zeiss) with 20Â, 40Â or 63Â magnification objectives and the images were processed using Photoshop 7.0 software (Adobe Systems).
Quantitative RT-PCR (qPCR)
Total RNA was extracted using Trizol RNA isolation kit or RNAeasy mini kit (Qiagen) according to the manufacturer's instructions (Invitrogen Corporation), and cDNA was synthesized with 5 lg total RNA using Moloney murine leukemia virus reverse transcriptase. Diluted cDNA was mixed with 2 Â SYBR Green PCR Master Mix and subjected to qPCR under the following conditions: an initial denaturation cycle of 95 C for 5 min, followed by 40 cycles of 15 s at 95 C and 1 min at 60 C in the RealTime PCR system. The relative amounts of mRNAs were normalized to GAPDH and RP49. Primer sequences used are shown in Supplementary Material, Table S1 .
Behavioral analysis
For locomotion assay, ten flies were placed in an empty vial with a mark 8 cm from the bottom. The flies were forced drop to the bottom of the tube, and the number of flies that crawl passed the 8-cm mark from bottom in 6 s was determined. Fifty flies per group were used and separated into five tubes contain ten flies. Each tube was analyzed 10 times, where the number of flies that passed the line was counted, and median values of 50 locomotor assays of ten flies per assay were calculated for each group. For olfactory associative learning assays, groups of $100 naïve flies received one training session, during which they were exposed sequentially to one odor (conditioned stimulus, CSþ; 3-octanol or 4-methyl-cyclohexanol) paired with electric shock (12 Â 1.5-s pulses of 75-V DC electric shock at 5-s interpulse intervals) and then a second odor (CS-; 4-methylcyclohexanol or 3-octanol) without electric shock. Conditioned odor avoidance was tested immediately after training. During testing, flies were exposed simultaneously to the CSþ and CSodors in a T-maze for 2 min. Then, flies were trapped in either T-maze arm, anesthetized, and counted. From this distribution, a performance index was calculated as the number of flies avoiding the shocked odor minus that avoiding the nonshocked odor divided by the total number of flies and multiplied by 100.
Statistical analysis
All data are expressed as the mean 6 SEM and analyzed by oneway analysis of variance (ANOVA). Statistical significance between groups was determined by one-way ANOVA, followed by Fisher's least significant difference (LSD) test using SPSS version 11.5. A p value less than 0.05 was considered statistically significant and marked with an asterisk in the figures.
Supplementary Material
Supplementary Material is available at HMG online.
